Literature DB >> 7934143

Characterization of bone marrow stromal cells from multiple myeloma.

M G Gregoretti1, D Gottardi, P Ghia, L Bergui, F Merico, P C Marchisio, F Caligaris-Cappio.   

Abstract

We have cultured multiple myeloma (MM) bone marrow (BM) stromal cells that are able to sustain the in vitro growth of monoclonal B-cells. Our aim was to evaluate which adhesion molecules are expressed and which extracellular matrix proteins are produced by these cells and whether they differ from the stromal cells that can be grown under the same experimental conditions from the BM of monoclonal gammopathies of undetermined significance (MGUS) and of normal donors. MM BM stromal cells that support malignant B-cell development have a striking proliferative ability that is absent in MGUS and normal donors of the same age group and are formed by four major different cell populations. Two kinds of HLA-DR+, CD10+ fibroblast-like cells can be recognized through the expression (or the lack) of alpha-smooth muscle actin isoform; further, macrophages and osteoclasts can be identified. Fibroblast-like cells that express alpha-smooth muscle actin isoform, often organized along stress fibers in a periodic fashion, may be considered as myofibroblasts. Fibroblast-like cells react strongly with antibodies to CD54 (ICAM-1), integrin beta 1, beta 3, beta 5 and some of associated alpha chains. Integrin beta 1 is diffusely exposed on the surface while beta 3 is clustered in focal contacts in association with vinculin. A still undetermined subpopulation of fibroblasts is highly positive for alpha v beta 5 that is clustered at focal contacts as shown by association with stress fiber termini and by interference reflection microscopy. A major difference between MM and normal donor BM stromal cells involves lower deposition and simpler organization of the extracellular matrix proteins (fibronectin, laminin, collagen type IV) deposited by MM fibroblast-like cells. CD14+ macrophages from MM, MGUS and normal donor BM are CD11a+ (alpha L), CD11b+ (alpha M), CD11c+ (alpha X), CD54+ (ICAM-1), CD56+ (N-CAM), beta 1 and beta 2 (CD18) integrin positive. The integrin beta 1 is diffusely expressed on the surface, while beta 2 is concentrated in podosomes. MM osteoclasts show a weak diffuse staining with CD54 and CD56 MoAbs; beta 1 integrin has a diffuse surface expression, while beta 3 integrin is concentrated in the podosomes. Normal donor osteoclasts are CD54- and the staining with CD56 is barely visible. These findings lead us to suggest that the microenvironment provided by MM BM may be significantly different from that of normal BM indicating its potential role in controlling the local proliferation and differentiation of malignant B-lineage cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7934143     DOI: 10.1016/0145-2126(94)90067-1

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

Review 1.  Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.

Authors:  Michaela R Reagan; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

2.  Cloning of a novel membrane-linked metalloproteinase from human myeloma cells.

Authors:  N McKie; D J Dallas; T Edwards; J F Apperley; R G Russell; P I Croucher
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

3.  Smooth muscle actin expression in primary bone tumours.

Authors:  F Hemingway; T G Kashima; G Mahendra; A Dhongre; P C W Hogendoorn; F Mertens; N A Athanasou
Journal:  Virchows Arch       Date:  2012-04-28       Impact factor: 4.064

4.  Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.

Authors:  Stephanie Markovina; Natalie S Callander; Shelby L O'Connor; Jihoon Kim; Jae E Werndli; Martha Raschko; Catherine P Leith; Brad S Kahl; Kyungmann Kim; Shigeki Miyamoto
Journal:  Mol Cancer Res       Date:  2008-08       Impact factor: 5.852

5.  Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.

Authors:  Jacqueline E Noll; Sharon A Williams; Christine M Tong; Hongsheng Wang; Julie M Quach; Louise E Purton; Katherine Pilkington; Luen B To; Andreas Evdokiou; Stan Gronthos; Andrew C W Zannettino
Journal:  Haematologica       Date:  2013-08-09       Impact factor: 9.941

6.  Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.

Authors:  J Corre; K Mahtouk; M Attal; M Gadelorge; A Huynh; S Fleury-Cappellesso; C Danho; P Laharrague; B Klein; T Rème; P Bourin
Journal:  Leukemia       Date:  2007-03-08       Impact factor: 11.528

7.  Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells.

Authors:  Stephanie Markovina; Natalie S Callander; Shelby L O'Connor; Guangwu Xu; Yufang Shi; Catherine P Leith; KyungMann Kim; Parul Trivedi; Jaehyup Kim; Peiman Hematti; Shigeki Miyamoto
Journal:  Mol Cancer       Date:  2010-07-06       Impact factor: 27.401

8.  Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.

Authors:  Barbara Zdzisińska; Agnieszka Bojarska-Junak; Anna Dmoszyńska; Martyna Kandefer-Szerszeń
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-05-30       Impact factor: 4.291

9.  Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?

Authors:  J E Noll; S A Williams; L E Purton; A C W Zannettino
Journal:  Blood Cancer J       Date:  2012-09-14       Impact factor: 11.037

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.